EyePoint (EYPT) Other financing activities (2011 - 2026)
EyePoint (EYPT) posted Other financing activities of $606000.0 for Q1 2026, up 72.65% sequentially from $351000.0 in Q4 2025, and up 170.54% YoY from $224000.0 in Q1 2025.
EyePoint (EYPT) Other financing activities (2011 - 2026) Analysis & Trends
EyePoint has reported Other financing activities for 14 years, with the latest figure at $606000.0 in Q1 2026.
- Quarterly Other financing activities rose 170.54% year-over-year to $606000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 55.45% YoY) and the FY2025 annual result came in at $1.5 million, down 73.39% from the prior year.
- Other financing activities advanced to $606000.0 in Q1 2026 per EYPT's latest filing, from $351000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $4.6 million in Q1 2024 and troughed at -$354000.0 in Q4 2022.
- A 5-year average of $662562.5 and a median of $262000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2024: Other financing activities tumbled 497.75% in 2022, then jumped 12400.0% in 2024.
- Over 5 years, Other financing activities stood at -$354000.0 in 2022, then jumped by 636.44% to $1.9 million in 2023, then slumped by 95.16% to $92000.0 in 2024, then soared by 281.52% to $351000.0 in 2025, then soared by 72.65% to $606000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $606000.0, $351000.0, and $623000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 597,000.00 |
| Jun 30, 2026 | 597,000.00 |
| Mar 31, 2026 | 606,000.00 |
| Mar 31, 2026 | 606,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 623,000.00 |
| Sep 30, 2025 | 623,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 4.56 Mn |
| Mar 31, 2024 | 4.56 Mn |